- Home
- SLS vs ACRS Comparison
SLS vs ACRS Comparison
Compare SLS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- ACRS
- Stock Information
- Founded
- SLS 2012
- ACRS 2012
- Country
- SLS United States
- ACRS United States
- Employees
- SLS N/A
- ACRS N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- SLS Health Care
- ACRS Health Care
- Exchange
- SLS Nasdaq
- ACRS Nasdaq
- Market Cap
- SLS 233.7M
- ACRS 198.2M
- IPO Year
- SLS N/A
- ACRS 2015
- Fundamental
- Price
- SLS $1.93
- ACRS $1.89
- Analyst Decision
- SLS Strong Buy
- ACRS Strong Buy
- Analyst Count
- SLS 1
- ACRS 9
- Target Price
- SLS $7.00
- ACRS $9.25
- AVG Volume (30 Days)
- SLS 2.5M
- ACRS 1.1M
- Earning Date
- SLS 11-12-2025
- ACRS 11-05-2025
- Dividend Yield
- SLS N/A
- ACRS N/A
- EPS Growth
- SLS N/A
- ACRS N/A
- EPS
- SLS N/A
- ACRS N/A
- Revenue
- SLS N/A
- ACRS $16,789,000.00
- Revenue This Year
- SLS N/A
- ACRS N/A
- Revenue Next Year
- SLS N/A
- ACRS $7.02
- P/E Ratio
- SLS N/A
- ACRS N/A
- Revenue Growth
- SLS N/A
- ACRS N/A
- 52 Week Low
- SLS $0.77
- ACRS $1.05
- 52 Week High
- SLS $2.27
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- SLS 59.08
- ACRS 48.51
- Support Level
- SLS $1.81
- ACRS $1.81
- Resistance Level
- SLS $1.92
- ACRS $1.94
- Average True Range (ATR)
- SLS 0.10
- ACRS 0.09
- MACD
- SLS 0.03
- ACRS -0.01
- Stochastic Oscillator
- SLS 87.67
- ACRS 27.51
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.